Matthew J Adamow

10PUBLICATIONS
178CO-AUTHORS
Predictive and prognostic markersInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 12, 2026
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand

|Dec 01, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar

|Apr 09, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill

|Aug 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah

|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy, Hannah L Kalvin, Fiona D Ehrich

|Aug 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.

Ronglai Shen, Michael A Postow, Matthew Adamow

Pageof 2

Frequent Collaborators

6 joint publications

Phillip Wong

5 joint publications

Margaret K Callahan

4 joint publications

Ronglai Shen

4 joint publications

Katherine S Panageas